- In October 2024, Roche received FDA approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first companion diagnostic designed to identify gastric and GEJ cancer patients eligible for Astellas’ VYLOY therapy
- In June 2024, I-Mab, a global biotech company focused on developing differentiated immunotherapies for cancer, announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb
- In May 2024, Merck reported that the Phase 3 KEYNOTE-811 trial achieved its dual primary endpoint of overall survival for KEYTRUDA combined with trastuzumab and chemotherapy in patients with HER2-positive gastric or GEJ adenocarcinoma
- In April 2024, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the U.S. for treating adult patients with unresectable or metastatic HER2-positive solid tumors, including breast, lung, and gastric cancers, who have received prior systemic treatment and lack satisfactory alternatives
- In April 2024, Ono Pharmaceuticals announced the acquisition of Deciphera Pharmaceuticals in a USD 2.4 billion buyout, granting Ono access to Deciphera’s oncology candidates, including the CSF-1 inhibitor vimseltinib and the ULK kinase inhibitor DCC-3116
